Endometrial carcinoma is generally considered the most common gynecological malignancy. It frequently presents with vaginal bleeding. Both ultrasound and pelvic MRI are useful modalities for evaluation. The incidence is thought to be increasing. In the United States, there is a greater incidence among patients of European descent compared those of African American descent.
|Published (Last):||21 December 2018|
|PDF File Size:||13.54 Mb|
|ePub File Size:||1.30 Mb|
|Price:||Free* [*Free Regsitration Required]|
Objective: Currently, no clinically useful tumor marker is available for primary diagnosis in endometrial cancer. Human epididymis protein-4 HE-4 has high sensitivity and specificity as a tumor marker. Further, HE-4 has been shown to be elevated in early stage endometrial cancer and is more sensitive than CA In our study, CA and HE-4 reputation as a tumor marker for diagnosis of ovarian and endometrial cancer with the use of both the availability and affect the way we investigated the rate of diagnosis.
Materials and methods: Here 20 patients with ovarian cancer, 26 patients with endometrial cancer, which had been histologically diagnosed, and 40 healthy volunteers were included. Peripheral blood samples were taken and serum CA and HE-4 were tested. Receiver-operating characteristic ROC analysis was performed. For patients with ovarian cancer and healthy controls, the CA 0.
ROC analysis was performed. For endometrial cancer patients and healthy controls, the CA 0. Conclusion: In ovarian and endometrial cancer, wherein early diagnosis is the most important factor for prognosis and survival, HE-4 is a new serum tumor marker that can be used with the aim of noninvasive diagnoses.
For early diagnosis, the concomitant use of CA and HE-4 is more effective and reliable than using either of them alone. Keywords: Ovary; cancer; diagnosis; endometrium; tumor marker. No conflict of interest was declared by the authors.
Clipboard, Search History, and several other advanced features are temporarily unavailable. Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:.
Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection.
Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again.
Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily.
Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items. Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Full-text links Cite Favorites. Abstract in English , Turkish. Conflict of interest statement No conflict of interest was declared by the authors. Figures Figure 1. Figure 1. Figure 2. Figure 3. Figure 4. See this image and copyright information in PMC.
Similar articles [The values of serum human epididymis secretory protein 4 and CA assay in the diagnosis of ovarian malignancy]. Dong L, et al. PMID: Chinese. Zhang AM, Zhang P. Zhang AM, et al. Dewan R, et al. J Clin Diagn Res. Epub Jul 1. HE4 as a biomarker for ovarian and endometrial cancer management. Li J, et al. Expert Rev Mol Diagn. Diagnostic value of serum human epididymis protein 4 HE4 in ovarian carcinoma: a systematic review and meta-analysis.
Wu L, et al. Int J Gynecol Cancer. PMID: Review. Show more similar articles See all similar articles. Anastasi E, et al. Asian Pac J Cancer Prev. Full-text links [x] Free PMC article. Copy Download.
Objective: Endometrial cancer and uterine leiomyoma are the most common malignant and benign tumors in developed countries. In women operated for endometrial cancer, accompanying uterine myome is observed in high rates. The treatment of the premenopausal myomas is delayed after the menopause conservatively. Yet it is unclear whether this approach has any negative effect on possible endometrial cancer. The goal of this study is to investigate the relationship between premenopausal myomas and the prognostic factors of endometrial cancer.